| Chapter title |
Alphavirus-Based Vaccines
|
|---|---|
| Chapter number | 13 |
| Book title |
Recombinant Virus Vaccines
|
| Published in |
Methods in molecular biology, April 2017
|
| DOI | 10.1007/978-1-4939-6869-5_13 |
| Pubmed ID | |
| Book ISBNs |
978-1-4939-6867-1, 978-1-4939-6869-5
|
| Authors |
Kenneth Lundstrom, Lundstrom, Kenneth |
| Editors |
Maureen C. Ferran, Gary R. Skuse |
| Abstract |
Alphavirus-based vectors have been engineered from Semliki Forest virus, Sindbis virus, and Venezuelan equine encephalitis virus and applied for vaccine development. Immunization in preclinical animal models has been conducted with naked RNA replicons, recombinant viral particles and layered DNA-RNA vectors. Most commonly, the targets for the immunization have been viral surface proteins and tumor antigens, which have elicited strong immune responses and even provided protection against challenges with lethal doses of virus and tumor cells, respectively. As alphaviruses also cause epidemics, vaccines have been developed against Chikungunya virus. Despite the success in several animal smodels only a few clinical trials have been conducted in humans, so far. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Denmark | 1 | 2% |
| Saint Kitts and Nevis | 1 | 2% |
| Unknown | 55 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 24% |
| Student > Ph. D. Student | 10 | 17% |
| Student > Bachelor | 6 | 10% |
| Other | 5 | 9% |
| Student > Master | 5 | 9% |
| Other | 11 | 19% |
| Unknown | 7 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 14 | 24% |
| Biochemistry, Genetics and Molecular Biology | 13 | 22% |
| Agricultural and Biological Sciences | 7 | 12% |
| Medicine and Dentistry | 6 | 10% |
| Psychology | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 10 | 17% |